Table 1.
Patient characteristics of the training group and the testing group (n = 1197)
|
Overal (n = 1197) |
Testing group (n = 360) |
Training group (n = 837) |
p | |
|---|---|---|---|---|
| Characteristics | Number of patients (%) | |||
| Age (%) | 0.41 | |||
| 20–35 | 32 (2.7) | 6 (1.7) | 26 (3.1) | |
| 35–59 | 504 (42.1) | 156 (43.3) | 348 (41.6) | |
| 60–84 | 594 (49.6) | 181 (50.3) | 413 (49.3) | |
| 85 + | 67 (5.6) | 17 (4.7) | 50 (6.0) | |
| Tumor size (%) | 0.09 | |||
| ≤ 2 cm | 155 (12.9) | 44 (12.2) | 111 (13.3) | |
| > 10 cm | 240 (20.1) | 61 (16.9) | 179 (21.4) | |
| 2.1-5 cm | 448 (37.4) | 153 (42.5) | 295 (35.2) | |
| 5.1-10 cm | 354 (29.6) | 102 (28.3) | 252 (30.1) | |
| Race (%) | 0.255 | |||
| Black | 849 (70.9) | 257 (71.4) | 592 (70.7) | |
| Other | 139 (11.6) | 48 (13.3) | 91 (10.9) | |
| White | 209 (17.5) | 55 (15.3) | 154 (18.4) | |
| Year of diagnosis (%) | 0.894 | |||
| 2010–2011 | 343 (28.7) | 100 (27.8) | 243 (29.0) | |
| 2012–2013 | 421 (35.2) | 127 (35.3) | 294 (35.1) | |
| 2014–2015 | 433 (36.2) | 133 (36.9) | 300 (35.8) | |
| Laterality (%) | 0.329 | |||
| Left | 631 (52.7) | 198 (55.0) | 433 (51.7) | |
| Right | 566 (47.3) | 162 (45.0) | 404 (48.3) | |
| Primary site (%) | 0.801 | |||
| Nipple | 5 (0.4) | 0 (0.0) | 5 (0.6) | |
| Central portion | 63 (5.3) | 18 (5.0) | 45 (5.4) | |
| Upper inner quadrant | 92 (7.7) | 27 (7.5) | 65 (7.8) | |
| Lower inner quadrant | 36 (3.0) | 11 (3.1) | 25 (3.0) | |
| Upper outer quadrant | 284 (23.7) | 85 (23.6) | 199 (23.8) | |
| Lower outer quadrant | 74 (6.2) | 20 (5.6) | 54 (6.5) | |
| Axillary tail | 7 (0.6) | 3 (0.8) | 4 (0.5) | |
| Overlapping lesion | 248 (20.7) | 70 (19.4) | 178 (21.3) | |
| Breast NOS | 388 (32.4) | 126 (35.0) | 262 (31.3) | |
| Histopathology (%) | 0.668 | |||
| Ductal | 959 (80.1) | 283 (78.6) | 676 (80.8) | |
| Lobular | 38 (3.2) | 13 (3.6) | 25 (3.0) | |
| Other | 200 (16.7) | 64 (17.8) | 136 (16.2) | |
| Grade (%) | 0.065 | |||
| I ~ II | 472 (39.4) | 141 (39.2) | 331 (39.5) | |
| III | 575 (48.0) | 162 (45.0) | 413 (49.3) | |
| Unknown | 150 (12.5) | 57 (15.8) | 93 (11.1) | |
| T stage (%) | 0.059 | |||
| T1 | 133 (11.1) | 38 (10.6) | 95 (11.4) | |
| T2 | 342 (28.6) | 121 (33.6) | 221 (26.4) | |
| T3 | 203 (17.0) | 51 (14.2) | 152 (18.2) | |
| T4 | 519 (43.4) | 150 (41.7) | 369 (44.1) | |
| N stage (%) | 0.158 | |||
| N0 | 270 (22.6) | 79 (21.9) | 191 (22.8) | |
| N1 | 575 (48.0) | 164 (45.6) | 411 (49.1) | |
| N2 | 162 (13.5) | 61 (16.9) | 101 (12.1) | |
| N3 | 190 (15.9) | 56 (15.6) | 134 (16.0) | |
| Marital status (%) | 0.705 | |||
| Married | 479 (40.0) | 138 (38.3) | 341 (40.7) | |
| Other | 219 (18.3) | 66 (18.3) | 153 (18.3) | |
| Unmarried | 499 (41.7) | 156 (43.3) | 343 (41.0) | |
| Bone metastasis (%) | 0.769 | |||
| No | 535 (44.7) | 166 (46.1) | 369 (44.1) | |
| Unknown | 12 (1.0) | 3 (0.8) | 9 (1.1) | |
| Yes | 650 (54.3) | 191 (53.1) | 459 (54.8) | |
| Brain metastasis (%) | 0.189 | |||
| No | 1036 (86.5) | 317 (88.1) | 719 (85.9) | |
| Unknown | 32 (2.7) | 5 (1.4) | 27 (3.2) | |
| Yes | 129 (10.8) | 38 (10.6) | 91 (10.9) | |
| Liver metastasis (%) | 0.821 | |||
| No | 828 (69.2) | 253 (70.3) | 575 (68.7) | |
| Unknown | 23 (1.9) | 6 (1.7) | 17 (2.0) | |
| Yes | 346 (28.9) | 101 (28.1) | 245 (29.3) | |
| HER2 (%) | 0.819 | |||
| Negative | 829 (69.3) | 252 (70.0) | 577 (68.9) | |
| Positive | 322 (26.9) | 93 (25.8) | 229 (27.4) | |
| Unknown | 46 (3.8) | 15 (4.2) | 31 (3.7) | |
| ER (%) | 0.766 | |||
| Negative | 347 (29.0) | 107 (29.7) | 240 (28.7) | |
| Positive | 850 (71.0) | 253 (70.3) | 597 (71.3) | |
| PR (%) | 0.401 | |||
| Negative | 525 (43.9) | 165 (45.8) | 360 (43.0) | |
| Positive | 672 (56.1) | 195 (54.2) | 477 (57.0) | |
| Surgery (%) | 0.506 | |||
| No | 857(71.6) | 263 (73.1) | 594 (71.0) | |
| Yes | 340 (28.4) | 97 (26.9) | 243 (29.0) | |
| Neoadjuvant therapy (%) | 0.241 | |||
| No | 1031 (86.1) | 317 (88.1) | 714 (85.3) | |
| Yes | 166 (13.9) | 43 (11.9) | 123 (14.7) | |
| Chemotherapy (%) | 0.983 | |||
| No | 481 (40.2) | 144 (40.0) | 337 (40.3) | |
| Yes | 716 (59.8) | 216 (60.0) | 500 (59.7) | |
| Radiotherapy (%) | 0.903 | |||
| No/refuse/unknown | 806 (67.3) | 241 (66.9) | 565 (67.5) | |
| Yes | 391 (32.7) | 119 (33.1) | 272 (32.5) | |
| Status (%) | 1 | |||
| Alive | 387 (32.3) | 116 (32.2) | 271 (32.4) | |
| Dead | 810 (67.7) | 244 (67.8) | 566 (67.6) | |
Ductal invasive ductal carcinoma, Lobular invasive lobular carcinoma